Quantum Intelligence Corp.
QIC combines quantum computing, artificial intelligence and deep domain expertise to build a new generation of industrial intelligence—and turn it into solutions and proprietary assets across drug discovery and finance.
01 / Who We Are
QIC was created to move beyond the limits of conventional computing and lead high-value transformation in drug discovery and finance. We develop Quantum–AI technologies, apply them to critical industry bottlenecks and convert their capabilities into scalable solutions, validated outcomes and proprietary assets.
Our ambition is not limited to advancing quantum research. QIC is building technologies and business models capable of changing how complex industrial decisions, discoveries and optimizations are made.
We concentrate on drug discovery and finance—two fields where computational complexity, economic value and the need for domain expertise converge.
QIC began with a belief that advanced science should do more than explain the world—it should help change real outcomes. After years in academic research, founder Choi Hwan-ho turned his attention to drug discovery, where long development cycles, high failure rates and unresolved molecular complexity continued to limit progress.
His research into molecular electron distributions offered a different starting point: understanding biological behavior through the underlying physics and chemistry that govern it. That work became the foundation of QIC’s technology and continues to shape its approach today—combining quantum methods, artificial intelligence and domain expertise to address complex problems with measurable industrial value.
Science creates its greatest value when it changes real-world outcomes.QIC · FOUNDING PERSPECTIVE
02 / What Makes QIC Different
QIC combines frontier computing, deep domain knowledge, real-world validation and proprietary assets within one operating model.
THE QIC OPERATING MODEL
Technology and domain expertise meet in validation, supporting solutions and proprietary drug programs.
Explore the technology ↗We determine where quantum methods can create value and integrate them with AI and conventional computing.
AI, quantum methods and classical computation are selected around the objective, data and constraints.
Technology & methodology ↗Internal expertise in drug discovery and finance enables QIC to define the right problem, data and validation criteria.
Drug-discovery expertise connects molecular science with candidate development. Financial expertise connects prediction with operational constraints.
QUEST™ & FintelliQ™ ↗Industry PoCs, joint development and proprietary programs validate technology against real data and outcomes.
Financial PoCs and drug-development programs connect computational results with industry data and experimental validation.
Financial PoC ↗Drug-development application ↗Platform solutions and owned drug assets create multiple paths to commercialization and enterprise value.
QUEST™ and FintelliQ™ form the solution portfolio. QIC’s own drug programs create a separate path through proprietary development and partnering.
Proprietary pipeline ↗03 / Selected Publications
QIC brings together expertise rarely found within a single team: physics and quantum science, chemistry and molecular design, and drug discovery and biology. This integrated research team connects fundamental science with industrial applications.
SCI-level and above publications
23publications
Physical Review Letters
2015 · Vol.115 · No.19
Read paper ↗
J. Chem. Theory & Comput.
2015 · Vol.11
Read paper ↗18publications
Science
2019 · Vol.366 · No.6466
Read paper ↗
J. Am. Chem. Soc.
2018 · Vol.140 · No.27
Read paper ↗39publications
Nature Communications
2023 · Vol.14 · Article 5654
Read paper ↗
Nature
2018 · Vol.555 · No.7697
Read paper ↗Journal covers are representative images; paper links lead to the original publications.
04 / Leadership & Organization
QIC’s leadership combines research credentials from Oxford, IBM T.J. Watson, KAIST, UCSF, UNIST and global pharmaceutical companies with the business experience required to translate science into industrial value.
MD · PhD · Quantum Chemistry · Drug Discovery
MD in Medicine, Kyunghee University · Oxford PhD in Chemistry · SNU Physics
AstraZeneca and KRIBB researcher
PhD · Quantum · Machine-Learning Algorithms
IBM T.J. Watson Research Center · KRIBB
University of Maryland PhD in Chemical Physics
SNU Physics & Computer Science
PhD · Biophysics · Protein Structural Biology
University of California, San Francisco researcher
University of Illinois Urbana-Champaign PhD in Physics · SNU Physics
PhD · Quantum-Chemistry Reactions · Catalysis
UNIST Research Assistant Professor · KIST and UNIST postdoctoral researcher · SK Innovation
SNU PhD in Physics
PhD · Clinical · R&D · External Affairs
inVentiv Health VP · Dong Wha Pharm Overseas Business Director · Global pharmaceutical industry experience
Helsinki School of Economics MBA
MS/BS, Seoul National University — Physical Pharmacy / Pharmacy
Commercialization · Strategy · Marketing
LG Electronics · Samsung C&T · CJ · Megabox Head of Marketing
New business planning, marketing strategy and brand communications
BA in Journalism and Mass Communication, Korea University
QUEST™, candidate discovery, preclinical prediction and proprietary pipeline development.
FintelliQ™, credit intelligence, optimization and financial industry validation.
Quantum chemistry, molecular computation and the scientific foundation of drug discovery.
Strategy, business development, partnerships, marketing and corporate operations.
05 / Strategic Partnerships
QIC’s partnership network connects quantum infrastructure, academic expertise, experimental validation and real industry data to accelerate Quantum–AI development and application.
06 / Explore QIC
Explore the people, partnerships and technologies behind QIC—or start a conversation about research, business and investment opportunities.